Zurcher Kantonalbank (Zurich Cantonalbank) Astria Therapeutics, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $34.1 Billion
- Q4 2024
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 9,249 shares of ATXS stock, worth $65,760. This represents 0.0% of its overall portfolio holdings.
Number of Shares
9,249Holding current value
$65,760% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
116Shares Held
48.7MCall Options Held
48KPut Options Held
9.3K-
Perceptive Advisors LLC New York, NY6.49MShares$46.1 Million1.87% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.11MShares$36.3 Million0.78% of portfolio
-
Vestal Point Capital, LP New York, NY4MShares$28.4 Million3.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$25.3 Million6.36% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$25 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $108M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...